Randomization to once-daily stavudine extended release/lamivudine/efavirenz versus a more frequent regimen improves adherence while maintaining viral suppression

HIV Clinical Trials

Volumn 9, Issue 3, 2008, Pages 164-176

  Boyle, Brian A ^a   Jayaweera, Dushyantha ^b   Witt, Mallory D ^c   Grimm, Kristy ^d   Maa, Jen Fue ^d   Seekins, Daniel W ^d  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d BRISTOL MYERS SQUIBB   (United States)

Author keywords

Adherence; Efavirenz; HIV; Once daily dosing; Regimen simplification; Switch

Indexed keywords

ABACAVIR; EFAVIRENZ; LAMIVUDINE; STAVUDINE; ZIDOVUDINE;

ABNORMAL DREAMING; ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED DRUG RELEASE; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DOSAGE SCHEDULE COMPARISON; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EXTENDED RELEASE FORMULATION; FATIGUE; FEMALE; GLUCOSE BLOOD LEVEL; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERLIPIDEMIA; HYPERTENSION; INSOMNIA; LIMB PAIN; LIPOATROPHY; LIPODYSTROPHY; MAJOR CLINICAL STUDY; MALE; OPEN STUDY; OUTCOME ASSESSMENT; PARESTHESIA; PATIENT COMPLIANCE; PATIENT SAFETY; PATIENT SATISFACTION; PERIPHERAL NEUROPATHY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SKIN ABSCESS; SOMNOLENCE; STUPOR; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; BENZOXAZINES; DRUG ADMINISTRATION SCHEDULE; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; LAMIVUDINE; MALE; MIDDLE AGED; PATIENT COMPLIANCE; RNA, VIRAL; STAVUDINE; VIRAL LOAD; VIRUS REPLICATION;

EID: 45949108248     PISSN: 15284336     EISSN: None     Source Type: Journal    
DOI: 10.1310/hct0903-164     Document Type: Article

References (36)

1. Kress KD. HIV update: emerging clinical evidence and a review of recommendations for the use of highly active antiretroviral therapy. Am J Health Syst Pharm. 2004;61 (suppl 3):S3-S14.
2. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among subjects with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med. 1998;338:853-860.
3. Holtzer CD, Roland M. The use of combination antiretroviral therapy in HIV-infected patients. Ann Pharmacother. 1999;33:198-209.
4. Vittinghoff E, Scheer S, O'Malley P, et al. Combination antiretroviral therapy and recent declines in AIDS incidence and mortality. J Infect Dis. 1999;179:717-720.
5. Mocroft A, Ledergerber B, Katlama C, et al. Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet. 2003;362:22-29.
6. Sethi AK, Celentano DD, Gange SJ, et al. Association between adherence to antiretroviral therapy and human immunodeficiency virus drug resistance. Clin Infect Dis. 2003; 37:1112-1118.
7. Bangsberg DR, Acosta EP, Gupta R, et al. Adherence-resistance relationships for protease and non-nucleoside reverse transcriptase inhibitors explained by virological fitness. AIDS. 2006;20:223-231.
8. Nachega JB, Hislop M, Dowdy DW, et al. Adherence to nonnucleoside reverse transcriptase inhibitor-based HIV therapy and virologic outcomes. Ann Intern Med. 2007; 146:564-573.
9. Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med. 2000;133:21-30.
10. Lucas GM, Wu AW, Cheever LW. Adherence to antiretroviral therapy: an update of current concepts. Curr HIV/AIDS Rep. 2004;1:172-180.
11. Roge BT, Barfod TS, Kirk O, et al. Resistance profiles and adherence at primary virological failure in three different highly active antiretroviral therapy regimens: analysis of failure rates in a randomized study. HIV Med. 2004;5:344-351.
12. Stone VE, Jordan J, Tolson J, et al. Perspectives on adherence and simplicity for HIV infected patients on antiretroviral therapy: self-report of the relative importance of multiple attributes of highly active antiretroviral therapy (HAART) regimens in predicting adherence. J Acquir Immune Defic Syndr. 2004;36:808-816.
13. Vervoort S, Borleffs J, Hoepelman A, et al. Adherence in antiretroviral therapy: a review of qualitative studies. AIDS. 2007;21:271-281.
14. Fortin C, Joly V. Efavirenz for HIV-1 infection in adults: an overview. Expert Rev Anti Infect Ther. 2004;2:671-684.
15. Frampton JE, Croom KF. Efavirenz/emtricitabine/tenofovir disoproxil fumarate: triple combination tablet. Drugs. 2006;66:1501-1512.
16. Pozniak AL, Gallant JE, DeJesus E, et al. Tenofovir disoproxil fumarate, emtricitabine, and efavirenz versus fixed-dose zidovudine/lamivudine and efavirenz in anti-retroviral-naïve patients: virologic, immunologic, and mor-phologic changes - a 96-week analysis. J Acquir Immune Defic Syndr. 2006;43:535-540.
17. Riddler S, Haubrich R, DiRienzo G, et al. A prospective, randomized phase III trial of NRTI-, PI-, and NNRTI-sparing regimens for initial treatment of HIV-1. ACTG 5142. Presented at: 16th International AIDS Conference; August 13-18, 2006; Toronto, Canada.
18. Ruane P, Lang J, DeJesus E, et al. Pilot study of once-daily simplification therapy with abacavir/lamivudine/zidovudine and efavirenz for treatment of HIV-1 infection. HIV Clin Trials. 2006;7:229-236.
19. Fischl MA, Collier AC, Mukherjee AL, et al. Randomized open-label trial of two simplified, class-sparing regimens following a first suppressive three or four-drug regimen. AIDS. 2007;21:325-333.
20. Scherpbier HJ, Bekker V, Pajkrt D, et al. Once-daily highly active antiretroviral therapy for HIV-infected children: safety and efficacy of an efavirenz-containing regimen. Pediatrics. 2007;119:705-715.
21. Brett-Smith H, Reynolds L, Bessen L, Rutkiewicz V. Two-year analysis of stavudine extended-release/prolonged release capsules (XR/PRC) as compared to stavudine immediate-release (IR): efficacy and safety. Presented at: 43rd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy, September 14-17, 2003; Chicago, IL, USA. Abstract H843.
22. Maggiolo F, Ripamonti D, Arici C, et al. Simpler regimens may enhance adherence to antiretrovirals in HIV-infected patients. HIV Clin Trials. 2002;3:371-378.
23. Cina CS, Clase CM. The Illness Intrusiveness Rating Scale: a measure of severity in individuals with hyperhidrosis. Qual Life Res. 1999;8:693-698.
24. Clayson DJ, Wild DJ, Quarterman P, et al. A comparative review of health-related quality of life measures for use in HIV/AIDS clinical trials. Pharmacoeconomics. 2006; 24:751-765.
25. Cote JK, Godin G. Efficacy of interventions in improving adherence to antiretroviral therapy. Int J AIDS. 2005;16:335-343.
26. Portsmouth SD, Osorio J, McCormick K, et al. Better maintained adherence on switching from twice-daily to once-daily therapy for HIV: a 24-week randomized trial of treatment simplification using stavudine prolonged-release capsules. HIV Med. 2005;6:185-190.
27. Munakata J, Benner JS, Becker S, et al. Clinical and economic outcomes of nonadherence to highly active antiretroviral therapy in patients with human immunodeficiency virus. Med Care. 2006;44:893-899.
28. Eldred LJ, Wu AW, Chaisson RE, et al. Adherence to antiretroviral and pneumocystis prophylaxis in HIV disease. J Acquir Immune Defic Syndr Hum Retrovirol. 1998;18:117-125.
29. Nieuwkerk PT, Sprangers MA, Burger DM, et al. Limited patient adherence to highly active antiretroviral therapy for HIV-1 infection in an observational cohort study. Arch Intern Med. 2001 ;161:1962-1968.
30. Kerr T, Walsh J, Lloyd-Smith E, et al. Measuring adherence to highly active antiretroviral therapy: implications for research and practice. Curr HIV/AIDS Rep. 2005;2:200-205.
31. Cramer JA, Mattson RH, Prevey ML, et al. How often is medication taken as prescribed? A novel assessment technique. JAMA. 1989;261:3273-3277.
32. Maggiolo F, Ravasio L, Ripamonti D, et al. Similar adherence rates favor different virologic outcomes for patients treated with nonnucleoside analogues or protease inhibitors. Clin Infect Dis. 2005;40:158-163.
33. Arpinelli F, Bamfi F. The FDA guidance for industry on PROs: the point of view of a pharmaceutical company. Health Qual Life Outcomes. 2006;4:85-89.
34. Campo R, Cohen C, Grimm K, et al. Simplification from protease inhibitor- to efavirenz-based highly active antiretroviral therapy improves quality of life and adherence with low rates of virologic failure. Manuscript in preparation.
35. Barragan P, Fisac C, Podzamczer D. Switching strategies to improve lipid profile and morphologic changes. AIDS Rev. 2006;8:191-203.
36. Clifford DB, Evans S, Yang Y, et al. Impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals. Ann Intern Med. 2005;143:714-721.